{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T06:32:02Z","timestamp":1648708322421},"reference-count":18,"publisher":"Pharmaceutical Society of Japan","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2016]]},"DOI":"10.1248\/bpb.b16-00360","type":"journal-article","created":{"date-parts":[[2016,7,31]],"date-time":"2016-07-31T22:04:53Z","timestamp":1470002693000},"page":"1359-1363","source":"Crossref","is-referenced-by-count":0,"title":["&lt;i&gt;In Vitro&lt;\/i&gt; Enhancement of Carvedilol Glucuronidation by Amiodarone-Mediated Altered Protein Binding in Incubation Mixture of Human Liver Microsomes with Bovine Serum Albumin"],"prefix":"10.1248","volume":"39","author":[{"given":"Makoto","family":"Sekimoto","sequence":"first","affiliation":[{"name":"Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Takamori","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saki","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Taguchi","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. <i>N. Engl. J. Med.<\/i>, <b>334<\/b>, 1349\u20131355 (1996).","DOI":"10.1056\/NEJM199605233342101"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Horiuchi I, Nozawa T, Fujii N, Inoue H, Honda M, Shimizu T, Taguchi M, Hashimoto Y. Pharmacokinetics of <i>R<\/i>- and <i>S<\/i>-carvedilol in routinely treated Japanese patients with heart failure. <i>Biol. Pharm. Bull.<\/i>, <b>31<\/b>, 976\u2013980 (2008).","DOI":"10.1248\/bpb.31.976"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Honda M, Toyoda W, Shimizu T, Horiuchi I, Kayano Y, Taguchi M, Nozawa T, Inoue H, Hashimoto Y. UGT2B7*3 did not affect the pharmacokinetics of <i>R<\/i>- and <i>S<\/i>-carvedilol in healthy Japanese. <i>Drug Metab. Pharmacokinet.<\/i>, <b>22<\/b>, 382\u2013386 (2007).","DOI":"10.2133\/dmpk.22.382"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Fujimaki M, Murakoshi Y, Hakusui H. Assay and disposition of carvedilol enantiomers in humans and monkeys: evidence of stereoselective presystemic metabolism. <i>J. Pharm. Sci.<\/i>, <b>79<\/b>, 568\u2013572 (1990).","DOI":"10.1002\/jps.2600790704"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Neugebauer G, Akpan W, von M\u00f6llendorff E, Neubert P, Reiff K. Pharmacokinetics and disposition of carvedilol in humans. <i>J. Cardiovasc. Pharmacol.<\/i>, <b>10<\/b> (Suppl. 11), S85\u2013S88 (1987).","DOI":"10.1097\/00005344-198710004-00015"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Honda M, Nozawa T, Igarashi N, Inoue H, Arakawa R, Ogura Y, Okabe H, Taguchi M, Hashimoto Y. Effect of CYP2D6*10 on the pharmacokinetics of <i>R<\/i>- and <i>S<\/i>-carvedilol in healthy Japanese volunteers. <i>Biol. Pharm. Bull.<\/i>, <b>28<\/b>, 1476\u20131479 (2005).","DOI":"10.1248\/bpb.28.1476"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Honda M, Ogura Y, Toyoda W, Taguchi M, Nozawa T, Inoue H, Hashimoto Y. Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers. <i>Biol. Pharm. Bull.<\/i>, <b>29<\/b>, 772\u2013778 (2006).","DOI":"10.1248\/bpb.29.772"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Ishida K, Taira S, Morishita H, Kayano Y, Taguchi M, Hashimoto Y. Stereoselective oxidation and glucuronidation of carvedilol in human liver and intestinal microsomes. <i>Biol. Pharm. Bull.<\/i>, <b>31<\/b>, 1297\u20131300 (2008).","DOI":"10.1248\/bpb.31.1297"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Ishida K, Taguchi M, Akao T, Hashimoto Y. Involvement of the CYP1A subfamily in stereoselective metabolism of carvedilol in \u03b2-naphthoflavone-treated Caco-2 cells. <i>Biol. Pharm. Bull.<\/i>, <b>32<\/b>, 513\u2013516 (2009).","DOI":"10.1248\/bpb.32.513"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Ohno A, Saito Y, Hanioka N, Jinno H, Saeki M, Ando M, Ozawa S, Sawada J. Involvement of human hepatic UGT1A1, UGT2B4, and UGT2B7 in the glucuronidation of carvedilol. <i>Drug Metab. Dispos.<\/i>, <b>32<\/b>, 235\u2013239 (2004).","DOI":"10.1124\/dmd.32.2.235"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Fukumoto K, Kobayashi T, Komamura K, Kamakura S, Kitakaze M, Ueno K. Stereoselective effect of amiodarone on the pharmacokinetics of racemic carvedilol. <i>Drug Metab. Pharmacokinet.<\/i>, <b>20<\/b>, 423\u2013427 (2005).","DOI":"10.2133\/dmpk.20.423"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Horiuchi I, Kato Y, Nakamura A, Ishida K, Taguchi M, Hashimoto Y. Inhibitory and stimulative effects of amiodarone on metabolism of carvedilol in human liver microsomes. <i>Biol. Pharm. Bull.<\/i>, <b>33<\/b>, 717\u2013720 (2010).","DOI":"10.1248\/bpb.33.717"},{"key":"13","unstructured":"13) Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. <i>Am. Fam. Physician<\/i>, <b>76<\/b>, 391\u2013396 (2007)."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Ohyama K, Nakajima M, Suzuki M, Shimada N, Yamazaki H, Yokoi T. Inhibitory effects of amiodarone and its <i>N<\/i>-deethylated metabolite on human cytochrome P450 activities: Prediction of <i>in vivo<\/i> drug interactions. <i>Br. J. Clin. Pharmacol.<\/i>, <b>49<\/b>, 244\u2013253 (2000).","DOI":"10.1046\/j.1365-2125.2000.00134.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Takekuma Y, Takenaka T, Yamazaki K, Ueno K, Sugawara M. Stereoselective metabolism of racemic carvedilol by UGT1A1 and UGT2B7, and effects of mutation of these enzymes on glucuronidation activity. <i>Biol. Pharm. Bull.<\/i>, <b>30<\/b>, 2146\u20132153 (2007).","DOI":"10.1248\/bpb.30.2146"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Takekuma Y, Yagisawa K, Sugawara M. Mutual inhibition between carvedilol enantiomers during racemate glucuronidation mediated by human liver and intestinal microsomes. <i>Biol. Pharm. Bull.<\/i>, <b>35<\/b>, 151\u2013163 (2012).","DOI":"10.1248\/bpb.35.151"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Veronese ME, McLean S, Hendriks R. Plasma protein binding of amiodarone in a patient population: measurement by erythrocyte partitioning and a novel glass-binding method. <i>Br. J. Clin. Pharmacol.<\/i>, <b>26<\/b>, 721\u2013731 (1988).","DOI":"10.1111\/j.1365-2125.1988.tb05311.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Rowland A, Gaganis P, Elliot DJ, Mackenzie PI, Knights KM, Miners JO. Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for <i>in vitro<\/i>\u2013<i>in vivo<\/i> extrapolation. <i>J. Pharmacol. Exp. Ther.<\/i>, <b>321<\/b>, 137\u2013147 (2007).","DOI":"10.1124\/jpet.106.118216"}],"container-title":["Biological &amp; Pharmaceutical Bulletin","Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/39\/8\/39_b16-00360\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T19:36:33Z","timestamp":1498332993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/39\/8\/39_b16-00360\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b16-00360","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}